Innovative Immunotherapy Treatment Demonstrates 90% Success Rate in Patients with Multiple Myeloma
By HospiMedica International staff writers Posted on 09 Jun 2023 |
Multiple myeloma, the second most prevalent blood cancer, has been notoriously resistant to treatment. Until a few years ago, the prognosis for this disease, accounting for one percent of all cancers and 10% of blood cancers, was a mere two-year average life expectancy. The disease's incidence is on the rise, with a projected 176,000 diagnoses worldwide in 2023. Now, a new ray of hope has emerged for those suffering from blood cancer, after nearly 90% of patients who underwent a novel immunotherapy treatment for multiple myeloma showed signs of improvement. Even more impressively, more than half - 57% - achieved remission. Clinical trials for this treatment, called CAR-T, or chimeric antigen receptor T-cell therapy, are set to commence soon in the United States.
CAR-T therapy utilizes a patient’s healthy cells to destroy the cancerous ones. It involves isolating a patient’s T-cells – the proactive cells of the immune system with the ability to fight tumors – using an apheresis machine that separates the blood into red and white cells. Through genetic engineering, a virus and a genetic fragment that encodes a receptor targeting the cancer cells are introduced. These modified cells are then produced in large numbers and reinfused into the patient, where they proceed to seek out and destroy the multiple myeloma cells.
The CAR-T treatment was developed at the Hadassah Medical Organization (New York, NY, USA) in collaboration with researchers at Bar-Ilan University (Ramat Gan, Israel). Immix BioPharma (Los Angeles, CA, USA) has acquired the patent rights to the therapy and plans to soon commence clinical trials in the US with FDA approval likely within a year. The revolutionary concept of harnessing a patient’s own immune system cells to fight cancer cells was first put forward several decades ago. Since then, researchers at the Hadassah Medical Organization have spearheaded the development and promotion of CAR-T. By manufacturing CAR-T at Hadassah, the medical center has managed to make this formerly prohibitive treatment accessible. As the first and sole institution in Israel to develop, produce, and deliver CAR-T treatment, Hadassah is pioneering a field that holds the promise of CAR-T therapies for other cancer types in the future.
“These are dramatic results and offer enormous hope for patients who have a disease that, to date, has been incurable,” said Polina Stepensky, MD, a hematologist-oncologist, pediatrician and stem-cell transplantation expert who directs Hadassah’s Bone Marrow Transplantation Department. “Until now, this treatment has only been available in China and the United States at a cost of nearly USD 400,000 per patient treatment. Only 20% of those who need to receive it in those countries actually get it.”
Related Links:
Hadassah Medical Organization
Bar-Ilan University
Immix BioPharma
Latest Critical Care News
- Smart Bandages to Revolutionize Treatment of Chronic Wounds
- Portable System for Warming Blood and IV-Fluids Reduces Hypothermia Risk in Hemorrhaging Patients
- AI-Generated Real-Time Alerts for Declining Health Speeds Up Treatment and Reduces Hospital Deaths
- Breakthrough Computational Method Predicts Sudden Cardiac Death
- Ingestible Microbiome Sampling Pill to Help Diagnose Wide Range of Health Conditions
- GPS-Like Smart Pills with AI Provide Real-Time 3D Monitoring Of Gastrointestinal Health
- Bioengineering Breakthrough to Improve Bone Regeneration Treatments
- Soft Robots with Electronic Skins and Artificial Muscles to Provide Medical Treatment
- AI Camera Technology Helps Doctors Quickly Assess Severity of Infections
- Machine Learning Delivers Personalized Oxygenation for Patients on Ventilators
- New AI Algorithm Detects Rare Epileptic Seizures from EEG Data
- Facial Thermal Imaging Combined with AI Predicts Coronary Artery Disease
- AI Technology Predicts Cardiac Events 10 Years in Advance
- Recyclable ‘Smart Skin’ Monitors Biological Signals on Demand
- Novel Catheter to Reduce Risk for Associated Urinary Tract Infections and Sepsis
- AI Doubles Medical Professionals’ Accuracy in Reading EEG Charts of ICU Patients